Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 PAK signalling during the development and progression of cancer.

Literature DB >> 24505617

PAK signalling during the development and progression of cancer.

Maria Radu, Galina Semenova, Rachelle Kosoff, Jonathan Chernoff.

Abstract

p21-Activated kinases (PAKs) are positioned at the nexus of several oncogenic signalling pathways. Overexpression or mutational activation of PAK isoforms frequently occurs in various human tumours, and recent data suggest that excessive PAK activity drives many of the cellular processes that are the hallmarks of cancer. In this Review, we discuss the mechanisms of PAK activation in cancer, the key substrates that mediate the developmental and oncogenic effects of this family of kinases, and how small-molecule inhibitors of these enzymes might be best developed and deployed for the treatment of cancer.

Entities: CellLine Chemical Disease Gene Species

Mesh：

Substances：

Year: 2014 PMID： 24505617 PMCID： PMC4115244 DOI： 10.1038/nrc3645

Source DB: PubMed Journal: Nat Rev Cancer ISSN： 1474-175X Impact factor: 60.716

153 in total

1. Structure of PAK1 in an autoinhibited conformation reveals a multistage activation switch.

Authors: M Lei; W Lu; W Meng; M C Parrini; M J Eck; B J Mayer; S C Harrison
Journal: Cell Date: 2000-08-04 Impact factor: 41.582

2. Rac1 and RhoA as regulators of endothelial phenotype and barrier function in hypoxia-induced neonatal pulmonary hypertension.

Authors: Beata Wojciak-Stothard; Lillian Yen Fen Tsang; Ewa Paleolog; Susan M Hall; Sheila G Haworth
Journal: Am J Physiol Lung Cell Mol Physiol Date: 2006-01-20 Impact factor: 5.464

3. MicroRNA-7, a homeobox D10 target, inhibits p21-activated kinase 1 and regulates its functions.

Authors: Sirigiri Divijendra Natha Reddy; Kazufumi Ohshiro; Suresh K Rayala; Rakesh Kumar
Journal: Cancer Res Date: 2008-10-15 Impact factor: 12.701

4. In vivo SILAC-based proteomics reveals phosphoproteome changes during mouse skin carcinogenesis.

Authors: Sara Zanivan; Alexander Meves; Kristina Behrendt; Erwin M Schoof; Lisa J Neilson; Jürgen Cox; Hao R Tang; Gabriela Kalna; Janine H van Ree; Jan M van Deursen; Carol S Trempus; Laura M Machesky; Rune Linding; Sara A Wickström; Reinhard Fässler; Matthias Mann
Journal: Cell Rep Date: 2013-01-31 Impact factor: 9.423

5. Involvement of microRNA-224 in cell proliferation, migration, invasion, and anti-apoptosis in hepatocellular carcinoma.

Authors: Yizhou Zhang; Shoichi Takahashi; Akiko Tasaka; Tadahiko Yoshima; Hidenori Ochi; Kazuaki Chayama
Journal: J Gastroenterol Hepatol Date: 2013-03 Impact factor: 4.029

6. Altered cortical synaptic morphology and impaired memory consolidation in forebrain- specific dominant-negative PAK transgenic mice.

Authors: Mansuo L Hayashi; Se-Young Choi; B S Shankaranarayana Rao; Hae-Yoon Jung; Hey-Kyoung Lee; Dawei Zhang; Sumantra Chattarji; Alfredo Kirkwood; Susumu Tonegawa
Journal: Neuron Date: 2004-06-10 Impact factor: 17.173

7. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays.

Authors: D Pinkel; R Segraves; D Sudar; S Clark; I Poole; D Kowbel; C Collins; W L Kuo; C Chen; Y Zhai; S H Dairkee; B M Ljung; J W Gray; D G Albertson
Journal: Nat Genet Date: 1998-10 Impact factor: 38.330

8. Akt phosphorylation of serine 21 on Pak1 modulates Nck binding and cell migration.

Authors: Guo-Lei Zhou; Ya Zhuo; Charles C King; Benjamin H Fryer; Gary M Bokoch; Jeffrey Field
Journal: Mol Cell Biol Date: 2003-11 Impact factor: 4.272

9. PAK signaling in cancer.

Authors: Diana Zi Ye; Jeffrey Field
Journal: Cell Logist Date: 2012-04-01

10. Paxillin phosphorylation at Ser273 localizes a GIT1-PIX-PAK complex and regulates adhesion and protrusion dynamics.

Authors: Anjana Nayal; Donna J Webb; Claire M Brown; Erik M Schaefer; Miguel Vicente-Manzanares; Alan Rick Horwitz
Journal: J Cell Biol Date: 2006-05-22 Impact factor: 10.539

204 in total

1. PAK6 targets to cell-cell adhesions through its N-terminus in a Cdc42-dependent manner to drive epithelial colony escape.

Authors: Elizabeth M Morse; Xiaowen Sun; Jordan R Olberding; Byung Hak Ha; Titus J Boggon; David A Calderwood
Journal: J Cell Sci Date: 2015-11-23 Impact factor: 5.285

PAK signalling during the development and progression of cancer.

1. Structure of PAK1 in an autoinhibited conformation reveals a multistage activation switch.

2. Rac1 and RhoA as regulators of endothelial phenotype and barrier function in hypoxia-induced neonatal pulmonary hypertension.

3. MicroRNA-7, a homeobox D10 target, inhibits p21-activated kinase 1 and regulates its functions.

4. In vivo SILAC-based proteomics reveals phosphoproteome changes during mouse skin carcinogenesis.

5. Involvement of microRNA-224 in cell proliferation, migration, invasion, and anti-apoptosis in hepatocellular carcinoma.

6. Altered cortical synaptic morphology and impaired memory consolidation in forebrain- specific dominant-negative PAK transgenic mice.

7. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays.

8. Akt phosphorylation of serine 21 on Pak1 modulates Nck binding and cell migration.

9. PAK signaling in cancer.

10. Paxillin phosphorylation at Ser273 localizes a GIT1-PIX-PAK complex and regulates adhesion and protrusion dynamics.

1. PAK6 targets to cell-cell adhesions through its N-terminus in a Cdc42-dependent manner to drive epithelial colony escape.

Review 2. Signaling, Regulation, and Specificity of the Type II p21-activated Kinases.

3. Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth.

4. Protein kinase D1 (PKD1) phosphorylation on Ser²⁰³ by type I p21-activated kinase (PAK) regulates PKD1 localization.

Review 5. P21 activated kinases: structure, regulation, and functions.

6. PAK1 is a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome.

7. Molecular pathways: targeting the kinase effectors of RHO-family GTPases.

8. Targeting MYC sensitizes malignant mesothelioma cells to PAK blockage-induced cytotoxicity.

9. PAK1 inhibitor IPA-3 mitigates metastatic prostate cancer-induced bone remodeling.

10. Targeting the vulnerability to NAD⁺ depletion in B-cell acute lymphoblastic leukemia.